Following a year in which vaccine manufacturing plant Emergent BioSolutions spent many months in the headlines for botching 75 million Johnson & Johnson (J&J) COVID-19 vaccines, the federal government and…
Pfizer’s investigational antiviral, Paxlovid (07321332 plus ritonavir) cut the risk of COVID-19 associated hospitalizations and death by 89 percent compared to placebo in an interim analysis of a phase 2/3…
House Democrats Friday abruptly postponed a vote on the amended $1.85 trillion Build Back Better Act, with compromise, scaled-back provisions aimed at reducing the price of prescription drugs. Source: Drug…
Merck’s and Ridgeback Biotherapeutics’ oral COVID-19 medication got its first green light from a regulatory body this week when the UK approved it, making it the first oral antiviral medicine…
House Democrats were expected to vote as soon as last night on the revised Build Back Better Act — including compromise provisions meant to lower the price of prescription drugs.…
Two CAR-T treatments — one from Gilead Sciences and another from Bristol Myers Squibb (BMS) — trounced standard-of-care as second-line therapies for patients with relapsed or refractory large B-cell lymphomas…
Despite pleas for approval during a public comment period, the FDA’s Psychopharmacologic Drugs Advisory Committee failed yesterday to recommend Levo Therapeutics’ intrasanal carbetocin — an oxytocin analogue delivered via a…
Novartis has agreed to sell its approximately one-third voting stake in its competitor Roche back to Roche for $20.7 billion. Source: Drug Industry Daily
Bayer is investing in GRO Biosciences, a Boston-based company that is developing protein therapeutics for patients with autoimmune and metabolic diseases. Source: Drug Industry Daily
Spartan Chemical didn’t conduct validation studies for the water system used to manufacture drug products, among other quality lapses observed during a recent FDA inspection of the company’s Maumee, Ohio…